Last edition
News about "Monoclonal antibody therapy"
Ipsen Completes Acquisition of Memo Therapeutics AG
Ipsen has completed its acquisition of Memo Therapeutics AG, adding a first-in-class asset to strengthen its rare disease pipeline.
Monoclonal Antibody Therapy | 23/07/2026 | By News Bureau
Phase 2a study findings show RESP-X demonstrated safety, favourable dosing potential and encouraging efficacy signals, supporting further clinical development for respiratory patients colonised with Pseudomonas aeruginosa.
Monoclonal Antibody Therapy | 25/05/2026 | By News Bureau | 169
Hope Medicine Reports Positive Phase II Results for First-in-Class Endometriosis Drug
HMI-115 shows significant pain reduction without hormonal disruption, paving the way for global phase III trials.
Monoclonal Antibody Therapy | 26/03/2026 | By News Bureau | 293
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy